Nov. 10 at 4:32 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc (
$GYRE) – Gyre Reports 3Q25 With Several Clinical Trial Updates
Quarter Sales Were Driven By Etuary. Gyre reported Net Income of
$5.9 million or
$0.04 per basic share. Revenue of
$30.6 million showed year-over-year growth of 20.0%. This was driven by strength in Etuary with sales of
$27.7 million. Sales of Etorel and Contiva sales were of
$1.5 million and
$1.2 million respectively. At the end of 3Q25 on September 30, the company had
$80.3 in cash, equivalents, and securities.
Read more: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-gyre-reports-3q25-with-several-clinical-trial-updates
